Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Lilly adds suicide risk to Strattera

Posted by Cairo on September 29, 2005, at 21:02:39

In reply to Lilly adds suicide risk to Strattera, posted by jrbecker on September 29, 2005, at 9:36:01

Strattera definitely caused a first bout of major depression in my teen daughter, even at a relatively low dose. Weaned her off even before we had our next appointment with the pdoc and her mood improved. I guess that means caution for anything with an NRI component.

Would this suggest Chrousos' theory of high CRH/NE in some types of depression?

Cairo

> http://news.yahoo.com/s/nm/20050929/hl_nm/lilly_dc
>
> Lilly adds suicide risk to Strattera
>
> Eli Lilly and Co. on Thursday said it will add strong warnings to its label for Strattera, used to treat attention-deficit/hyperactivity disorder, including the risk of suicidal thoughts among children and adolescents.
>
> Strattera will now carry a "black box" warning, the strongest required by U.S. regulators.
>
> Lilly said there were no suicides among children, adolescents or adults taking the medication during Strattera clinical trials, but there was one suicide attempt in a patient taking the drug.
>
> The warning came after the U.S. Food and Drug Administration requested Lilly to submit an analysis of adverse event data from its Strattera clinical trials data base, which identified a small but statistically significant increased risk of suicidal thoughts among Strattera-treated children and adolescents.
>
> Lilly said it is working with the FDA to finalize the product label. It also is working with regulators outside the United States.
>
> Lilly backed its prior sales and earnings outlook for the year and said it expects to report full-year 2005 earnings per share of $1.90 to $1.96.
>
> ADHD affects 3 to 7 percent of school-age children and manifests itself in inappropriate levels of attention, concentration, activity, distractibility and impulsivity.
>
> Shares of Lilly closed at $53.47 on Wednesday on the New York Stock Exchange.
>
>


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Cairo thread:560940
URL: http://www.dr-bob.org/babble/20050927/msgs/561099.html